NCT04090528View on ClinicalTrials.gov

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

November 24, 2024

Study Completion Date

October 31, 2026

Conditions
Castration-resistant Prostate CancerMetastatic CancerProstate Cancer
Interventions
BIOLOGICAL

pTVG-HP

pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).

BIOLOGICAL

pTVG-AR

pTVG-AR is a plasmid DNA

DRUG

Pembrolizumab

Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.

Trial Locations (2)

53705

University of Wisconsin Carbone Cancer Center, Madison

63110

Washington University Siteman Cancer Center, St Louis

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Madison Vaccines Incorporated

INDUSTRY

collaborator

Prostate Cancer Foundation

OTHER

lead

University of Wisconsin, Madison

OTHER

NCT04090528 - pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter